NCT02923466 is a Phase 1 clinical trial of VSV-IFNβ-NIS in Malignant Solid Tumour, sponsored by Vyriad, Inc..

Who is sponsoring NCT02923466?

NCT02923466 is sponsored by Vyriad, Inc..

What drugs are being tested in NCT02923466?

Interventions in NCT02923466: VSV-IFNβ-NIS, VSV-IFNβ-NIS and avelumab.

What condition does NCT02923466 study?

NCT02923466 studies Malignant Solid Tumour.

Is NCT02923466 still recruiting?

NCT02923466 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT02923466

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Completed Phase 1 Last updated 27 April 2022

What this trial tests

Phase 1 trial testing VSV-IFNβ-NIS in Malignant Solid Tumour in 76 participants. Completed in 22 April 2022.

Timeline

17 April 2017

Primary endpoint
5 February 2022

22 April 2022

Quick facts

Lead sponsor	Vyriad, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	17 April 2017
Primary completion	5 February 2022
Estimated completion	22 April 2022
Sites	6 locations across United States

Drugs / interventions tested

VSV-IFNβ-NIS — full drug profile →
VSV-IFNβ-NIS and avelumab — full drug profile →

Conditions studied

Malignant Solid Tumour — all drugs for Malignant Solid Tumour →

Sponsor

Vyriad, Inc. — full company profile →

Who can join

18 and older, any sex, with Malignant Solid Tumour. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV VSV-IFNβ-NIS, with or without IV avelumab every two weeks, in patients with refractory advanced/metastatic solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S, Bechmann N, Taieb D, Beuschlein F, et al · · 2022 · cited 281× · PMID 34147030 · DOI 10.1210/endrev/bnab019
Type I interferon-mediated tumor immunity and its role in immunotherapy.
Yu R, Zhu B, Chen D. · · 2022 · cited 229× · PMID 35292881 · DOI 10.1007/s00018-022-04219-z
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T, Song X, Wang Y, Liu F, et al · · 2020 · cited 134× · PMID 32411132 · DOI 10.3389/fimmu.2020.00683
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.
Sivanandam V, LaRocca CJ, Chen NG, Fong Y, et al · · 2019 · cited 124× · PMID 31080879 · DOI 10.1016/j.omto.2019.04.003
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.
Rahman MM, McFadden G. · · 2021 · cited 107× · PMID 34771615 · DOI 10.3390/cancers13215452
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L, Peng KW, Russell SJ, Diaz RM. · · 2019 · cited 93× · PMID 31321623 · DOI 10.1007/s40259-019-00367-0
Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.
Felt SA, Grdzelishvili VZ. · · 2017 · cited 91× · PMID 29143726 · DOI 10.1099/jgv.0.000980
Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S, Tiwari R, Gupta S, Byrareddy SN, et al · · 2018 · cited 85× · PMID 29473868 · DOI 10.3390/v10020090

Verify or expand the search:

Other trials of VSV-IFNβ-NIS

Trials testing the same drug.

NCT03647163 — Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tu · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for Malignant Solid Tumour

Currently open trials in the same condition.

NCT07044336 — Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) · Phase 3 · recruiting

Other Vyriad, Inc. trials

Trials by the same sponsor.

NCT03647163 — Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tu · Phase 1, PHASE2 · active not recruiting
NCT03171493 — Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy · Phase 1 · completed
NCT02919449 — Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02923466 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vyriad, Inc.
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02923466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing